Regeneron Pharmaceuticals Inc

A Delaware federal judge on Monday rejected requests from Pfizer, BioNTech and Moderna to dismiss lawsuits filed by Bayer's Monsanto unit over their use of US Patent No. 7,741,118, a patent related to mRNA technology, with Judge William Bryson saying the companies failed to prove the patent was invalid or not infringed by their COVID-19 vaccines. Sanofi agreed to a deal worth up to $8B, including $1B upfront, with Regeneron to jointly develop four long-acting immunology therapies, led by the clinical-stage IL-13 monoclonal antibody REGN20423. China's Abogen Biosciences signed a licensing and option agreement with Novartis worth up to $7.8B, comprising a $575 million upfront payment and up to approximately $7.2 billion in potential milestone payments if all options on all programs are exercised, covering an exclusive worldwide license to Abogen's lead asset ABO2203. Jiangsu Hengrui Pharmaceuticals agreed to license global rights to its experimental obesity drug HRS-1596 to Novo Nordisk in a deal worth up to $2.6B, with $300M upfront and the transaction expected to close in Q4 2026. Meanwhile, the S&P 500 Health Care Sector Index slipped 2.66% for the week, with Incyte down 6.93% and Regeneron down 6.71% among the top decliners, while McKesson rose 4.11% and Cardinal Health gained 3.67%.

Sanofi and Regeneron Pharmaceuticals have expanded their longstanding antibody collaboration to include four next-generation, long-acting antibodies targeting type II inflammation. Under the agreement, the companies will co-develop and co-commercialize four Regeneron-invented antibodies targeting IL-13, an IL-4xIL-13 bispecific, IL-4 and IL-4Rα, with one program, REGN20423, a long-acting IL-13 monoclonal antibody, currently in a phase I study for atopic dermatitis and the other three expected to enter clinical studies in 2027. Regeneron is entitled to a $1 billion upfront payment from Sanofi and up to $7 billion in additional development, regulatory and commercial milestone payments, while the two will equally share development and commercialization costs and future profits globally, with Regeneron leading research and development and Sanofi overseeing global commercial efforts. Regeneron will also have an option to include Sanofi's investigational candidate lunsekimig, a bispecific nanobody therapy targeting TSLP and IL-13, in the collaboration after completion of its phase III studies in chronic obstructive pulmonary disease, and the companies agreed to settle their prior collaboration-related litigation. The expanded collaboration builds on a more than 20-year alliance that established Dupixent as a widely used treatment for type II inflammation, with more than 1.5 million people currently receiving the drug across nine indications, and the existing profit-sharing agreement for Dupixent will remain unchanged.

Regeneron Pharmaceuticals announced new Phase 2 COURAGE trial results showing that trevogrumab prevented 70% of the muscle loss associated with semaglutide treatment in people living with obesity. In a predefined MRI substudy, lower-dose trevogrumab preserved almost 70% of the thigh muscle that would otherwise have been lost with semaglutide alone, with 71.8% preservation at 52 weeks for the 25 mg dose and 68.9% for the 75 mg dose relative to placebo plus semaglutide. The lower-dose portion of the trial, which evaluated trevogrumab at 25 mg or 75 mg in combination with semaglutide 2.4 mg over 52 weeks, replicated the higher-dose findings, preserving lean mass at both 26 and 52 weeks, the primary endpoint, though it did not meaningfully enhance weight loss achieved with semaglutide alone. A pre-specified subgroup analysis found that patients meeting the low lean mass definition for sarcopenia had greater loss of lean mass with semaglutide and more preservation with trevogrumab. The results were presented at the European Association for the Study of Diabetes Annual Meeting and are in press with The Lancet, and Regeneron is planning to initiate a Phase 2 trial of trevogrumab in combination with GLP-1 receptor agonist-based therapies in older adults with obesity and decreased muscle mass and/or strength.

Regeneron Pharmaceuticals executives told Bernstein analyst Jeffrey Walch that EYLEA HD, Dupixent and Libtayo each reached all-time quarterly net sales, with EYLEA HD accounting for roughly 60% of EYLEA franchise net sales in the second quarter. Chief financial officer Chris Fenimore said Regeneron expects sequential demand growth for EYLEA in the low- to mid-teens percentage range in both the third and fourth quarters despite additional biosimilar competition in the 2-milligram market, and that the company paid off its Sanofi development balance in the second quarter, a move expected to lift earnings from the Sanofi collaboration beginning in the third quarter. Dupixent is annualizing at approximately $24 billion in sales, including approximately $18 billion in the U.S., while Libtayo sales rose more than 30% year over year and now rank second in both new-to-brand and total share in U.S. lung cancer. On the pipeline, the FDA action date for cemdisiran in generalized myasthenia gravis is in November, registration-enabling PNH data are expected in the fourth quarter, and further readouts are anticipated in MASH, Factor XI and melanoma. Regeneron repurchased approximately $2 billion of stock in the first half, including $1.2 billion in the second quarter, and pays roughly $400 million annually under a dividend program begun in 2025.

DelveInsight estimates the paroxysmal nocturnal hemoglobinuria market across the seven major markets was valued at approximately USD 1.5 billion in 2025 and is projected to expand at a CAGR of 7.1% through 2036, driven by novel complement-targeted therapies and rising diagnosis. The seven major markets comprise the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. Five emerging therapies are highlighted as poised to reshape the market: Regeneron Pharmaceuticals' Pozelimab plus Cemdisiran, Novo Nordisk's Zaltenibart, also known as OMS906, NovelMed Therapeutics' Ruxoprubart, also known as NM8074, Kira Pharmaceuticals' KP104, and NovelMed Therapeutics' NM5072. Aparna Thakur, Project Manager of Forecasting and Analytics at DelveInsight, said Pozelimab is expected to generate the highest revenue in the 7MM, followed by Zaltenibart, which demonstrated strong efficacy in a Phase II study in PNH patients with suboptimal responses to ravulizumab. Regeneron has said Phase III results for the pozelimab-cemdisiran combination in PNH are anticipated in the fourth quarter of 2026 or the first quarter of 2027, while Novo Nordisk gained exclusive worldwide rights to zaltenibart through an asset purchase and license agreement with Omeros Corporation announced in November 2025.

Veeva Systems announced that Regeneron and Biogen have adopted its AI-powered Vault CRM suite globally, and introduced Veeva Falcon Safety, a new agentic safety operations product for biopharma clients. These moves expand Veeva's AI-focused offerings across commercial and safety workflows in life sciences, reinforcing its position as a key provider of industry-specific cloud software. With a market cap of about $45.5 billion, Veeva is a large specialist in healthcare software, and these global commitments signal deeper integration of its AI tools into core biopharma operations, potentially increasing switching costs and making multi-year relationships more durable. The company plans a November 2026 rollout for Falcon Safety, and investors will watch for early adopters and quantified updates in upcoming earnings calls to gauge traction.

Regeneron Pharmaceuticals has received FDA approval for Pasatru (garetosmab) to treat adults with fibrodysplasia ossificans progressiva, a rare and severely debilitating condition, based on a positive Phase 3 trial. This approval adds a new rare disease therapy to Regeneron's portfolio and introduces a fresh product-based revenue stream, though the FOP indication is very small, so the near-term financial impact is likely modest for the US$80.7 billion company. The approval is more significant as proof that Regeneron's R&D and antibody platforms continue to produce approved, differentiated medicines in highly targeted settings. Investors will watch how quickly Pasatru is adopted across eligible FOP centers, payer responses to pricing and access, and whether the planned Phase 3 OPTIMA 2 study in adolescents and children initiates on schedule and progresses without major setbacks.

Regeneron Pharmaceuticals has committed to Veeva Vault CRM globally, expanding its strategic partnership with Veeva Systems. With Vault CRM, Regeneron plans to generate Commercial Evidence from AI-powered field engagement, uncovering hidden barriers to treatment adoption and ensuring medicines reach eligible patients. Ryan Steinberger, executive vice president and chief digital and technology officer at Regeneron, said the move will give commercial teams a more connected platform and faster access to information for efficient decision-making. Vault CRM is part of the Vault CRM Suite of applications that provide the technology foundation for commercial execution.

Telix Pharmaceuticals Limited announced its half-year 2026 financial results, reporting group revenue of US$477 million, up 22% year-over-year and tracking in line with the upper end of full-year guidance of US$950 million to US$970 million. Group gross margin improved to 55%, while adjusted EBITDA surged 146% to US$52 million, boosted by a US$40 million non-refundable payment from a new strategic collaboration with Regeneron to develop next-generation radiopharmaceutical therapies. The company also completed a refinancing of its convertible bonds, issuing US$600 million of new notes due 2031, and posted a profit after tax of US$38 million. Telix reaffirmed its full-year revenue and other income expectation of over US$1 billion, including the Regeneron payment, and R&D expenditure guidance of US$230 million to US$270 million. Additionally, Telix entered into an at-the-market equity distribution agreement with Morgan Stanley and William Blair to potentially issue American Depositary Shares on Nasdaq.

The U.S. Food and Drug Administration has approved Regeneron Pharmaceuticals' Pasatru (garetosmab-grts) to reduce new heterotopic ossification lesions and clinician-assessed flare-ups in adults with fibrodysplasia ossificans progressiva. Approval was based on the Phase 3 OPTIMA trial, which showed a 90% or greater reduction in new HO lesions at 56 weeks compared to placebo. The recommended starting dosage is 10 mg/kg intravenously once monthly, with a possible decrease to 3 mg/kg if not tolerated. Pasatru is a fully human monoclonal antibody that blocks Activin A, a protein critical in the development of HO lesions. Regeneron plans to begin a Phase 3 trial in adolescents and children later this year, and regulatory submissions are under review in the European Union and planned in Japan.

EyePoint Pharmaceuticals announced that its investigational wet age-related macular degeneration treatment Duravyu failed to meet the primary endpoint of non-inferiority on best corrected visual acuity versus Regeneron's Eylea in the first of two pivotal phase III studies, sending its shares down 67% on Monday. The LUGANO study enrolled 211 patients and was affected by an asymmetric cohort of nine patients, about 4% of the group, who experienced vision loss of at least 15 letters that EyePoint said was unrelated to wet AMD, while no Eylea patients had similar vision loss. An ad hoc analysis excluding those nine patients showed Duravyu was non-inferior to Eylea, and the candidate achieved a 42% reduction in treatment burden, meeting the threshold for superiority. Duravyu also demonstrated favorable durability, with 54% of patients remaining supplement-free through week 56, and safety was comparable to Eylea with no cases of insert migration or severe intraocular inflammation. EyePoint expects top-line results from the identical LUCIA study in the fourth quarter of 2026 and anticipates potentially submitting a new drug application in the first half of 2027, pending those results.

Regeneron Pharmaceuticals confirmed a quarterly dividend, released second quarter and half year 2026 results, and updated on recent share repurchases. The stock last closed at $784.36, which is 5.9% below a narrative fair value of $833.31. Its current P/E of 18.1x sits just above the US Biotechs industry average of 17.3x but well below a fair ratio of 26.1x. The company's pipeline includes recent or upcoming pivotal data in immunology, oncology, genetic medicines, and obesity, supporting future revenue growth. Key risks include pressure on EYLEA from competition and pricing, as well as setbacks from fianlimab and LAG 3 trial disappointments.

CytomX Therapeutics announced second quarter 2026 financial results and a business update highlighted by progress of its lead candidate varsetatug masetecan, or Varseta-M, an EpCAM-directed antibody drug conjugate. The company expects a Phase 1 monotherapy data update in advanced colorectal cancer by the end of 2026 and plans to initiate a registrational study in the first half of 2027. Varseta-M is also being evaluated in combination with bevacizumab in late-line metastatic colorectal cancer, with a Phase 1/2 chemotherapy combination study in second-line disease set to start in the fourth quarter of 2026, and monotherapy expansion cohorts in gastric, pancreatic, and biliary tract cancers are initiating in the third quarter of 2026. CytomX expanded its Regeneron collaboration in masked bispecific immunotherapies, receiving a $37.0 million target selection payment in July 2026 for two additional programs, with total potential milestones under the collaboration now up to approximately $4.0 billion. The company reported cash, cash equivalents and investments of $330.3 million as of June 30, 2026, which does not include the $37.0 million received in July, and expects its cash runway to extend to at least the second half of 2028.

The healthcare sector gained about 2.45% in July, outperforming the broader S&P 500 which slipped around 0.12%. Regeneron Pharmaceuticals was the biggest winner, climbing 22.08%, followed by DexCom which gained 21.19% after its Q2 earnings beat and raised full-year guidance, and Baxter International which advanced 20.61%. Moderna was the biggest detractor, dropping 24.39%, while Intuitive Surgical fell 12.19% and managed-care insurers Humana, Elevance Health, and Centene also finished among the weakest performers. Earnings-driven gains in pharmaceuticals and medtech contrasted with weakness in managed-care insurers and vaccine makers.

Regeneron beat Wall Street estimates for second-quarter revenue and profit, driven by strong demand for its eczema drug Dupixent and a high-dose version of its eye drug Eylea. Global net sales of Dupixent, recorded by partner Sanofi, increased 38% to about $6 billion, surpassing estimates of $5.34 billion. Quarterly U.S. sales of the high-dose Eylea rose 52% to $596 million, while the lower-dose version faced competitive pressures. The company fully repaid the Sanofi Development Balance, which RBC Capital Markets analyst Brian Abrahams said should improve margins and make second-half numbers look much better. Quarterly revenue rose 17% to $4.29 billion, exceeding estimates of $3.82 billion, and non-GAAP adjusted profit was $14.29 per share, beating the estimate of $10.26.

Telix Pharmaceuticals reported a 21% increase in second-quarter revenue to $247 million and announced the first patient has been dosed in its Phase 3 LUTEON trial of TLX250-Tx in kidney cancer. Precision medicine revenue grew 30% to $202 million, while TMS revenue slipped 6% to $45 million. The company expects full-year 2026 revenue and other income to exceed $1 billion, with revenue tracking toward the upper end of its $950 million to $970 million guidance plus $40 million in non-refundable other income from a strategic collaboration with Regeneron. The LUTEON study is the first Phase 3 trial of a radiopharmaceutical therapy in clear cell renal cell carcinoma. Shares rose 4.05% in pre-market trading to $10.95.

Alnylam Pharmaceuticals announced the initiation of a global Phase 2 study of its investigational RNAi therapeutic mivelsiran in people with Down syndrome–associated Alzheimer's disease at the Alzheimer's Association International Conference 2026. The APPlauDS study will recruit participants with early-stage Alzheimer's across approximately 30 sites, marking the first clinical trial to evaluate an RNAi approach to reduce APP overexpression caused by trisomy 21. Alnylam also reported updated Phase 1 data in early-onset Alzheimer's disease showing no increased risk of amyloid-related imaging abnormalities and robust reductions in cerebrospinal fluid biomarkers, with mean maximum decreases of 89.9% for sAPPβ and 70.2% for Aβ42 in the highest dose group. The company completed enrollment in the Phase 2 cAPPricorn-1 study of mivelsiran in cerebral amyloid angiopathy, with initial results expected in 2028. Additionally, Alnylam presented preclinical data and the design of an ongoing Phase 1 trial for ALN‑5288, a tau-targeting RNAi therapeutic being developed in collaboration with Regeneron Pharmaceuticals.

HSBC lowered its price target on Regeneron Pharmaceuticals to $800 from $990 while maintaining a Buy rating, as part of a broader healthcare sector update. The firm highlighted therapeutics as offering attractive risk-adjusted opportunities. Separately, Regeneron announced that the FDA and EMA accepted regulatory submissions for cemdisiran as a potential treatment for generalized myasthenia gravis, with the FDA granting Priority Review and a target decision in November 2026.

Alnylam Pharmaceuticals reported $1.04 billion in net product revenues in the first quarter of 2026, a 121% year-over-year increase, driven by its four marketed drugs. Its newest drug, Amvuttra, generated $889.9 million in global sales, up 187% year-over-year, but faces competition in the ATTR-CM market from Pfizer's Vyndaqel family, which brought in $1.6 billion, and BridgeBio's Attruby, with $180.6 million in sales. Alnylam is advancing a broad pipeline to sustain long-term growth, including cemdisiran, for which Regeneron submitted a U.S. regulatory filing in April 2026 after positive phase III results in generalized myasthenia gravis, and zilebesiran, which has entered a global phase III cardiovascular outcomes study with Roche. The company is also developing mivelsiran for early-onset Alzheimer's disease and cerebral amyloid angiopathy, and nucresiran for ATTR amyloidosis, with phase III studies underway. Despite the pipeline progress, Alnylam's stock has fallen 21.4% year-to-date, and it carries a Zacks Rank #4 (Sell), with 2026 earnings estimates declining to $9.05 per share.

Regeneron Pharmaceuticals has received FDA acceptance with Priority Review for cemdisiran in generalized myasthenia gravis, and the EMA has also accepted the marketing application, aligning regulatory review on both sides of the Atlantic. Phase 3 trial data for cemdisiran were published in The Lancet, providing peer-reviewed clinical evidence. If approved, cemdisiran would be the first siRNA treatment for generalized myasthenia gravis and the only subcutaneous option with four-times-a-year dosing, potentially addressing an area of significant unmet need among the estimated 85,000 MG patients in the US and broader global prevalence. The FDA's Priority Review sets an action date in November 2026, with a planned Japan filing in early 2027. Regeneron's stock is at $654.27, down 15.7% year to date but up 20.2% over the past year.

Regeneron Pharmaceuticals stock has gained 20.2% over the past year, yet valuation checks still lean toward the shares looking inexpensive. The company trades on a price-to-earnings ratio of 15.0 times, below the biotech industry average of 17.3 times and a peer group average of 37.4 times. Simply Wall St's fair multiple suggests a P/E closer to 25.0 times, implying a sizeable gap to the current level. Regeneron screens as undervalued in all six areas assessed, pointing to the market price sitting below what these valuation tests suggest could be justified.